Kidney Cancer

A brief discussion elucidating the patient and caregiver perspectives when selecting a treatment option for renal cell carcinoma.

Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.

Comprehensive insight on how best to communicate potential adverse events and followup strategies with patients going on therapy for RCC.

Hans Hammers, MD, PhD, provides a broad overview on the treatment options available to patient who receive a diagnosis of renal cell carcinoma.

Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.

Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.

Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.

Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.

Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.

An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.

Expert and patient perspectives on the communication that occurs leading up to and following a diagnosis of renal cell carcinoma.

Healthcare professionals contextualize Terri Blalock’s experience by highlighting the typical presentation of RCC and elucidating workup procedures used to confirm a diagnosis.

Patients with advanced clear cell renal cell carcinoma are “unlikely” to experience a clinically meaningful decrease in overall survival following planned treatment cessation with a tyrosine kinase inhibitor.

Lenvatinib and pembrolizumab’s benefit proves to be long-lasting and significant in first-line advanced renal cell carcinoma, according to an expert from University of Bari 'A. Moro'.

Shared insight from Terri Blalock and her caregiver, Kaitlin Blalock, regarding the diagnosis of renal cell carcinoma Terri received following a number of symptoms.

Expert oncologist Hans Hammers, MD, PhD, spearheads an overview on renal cell carcinoma, covering its current incidence and known risk factors.

An ongoing exploratory biomarker analysis of the CheckMate 9ER trial set out to identify predictive biomarkers or a composite model of response of nivolumab/cabozantinib efficacy in advanced renal cell carcinoma.

Results from cohort A of the HCRN GU16-260 trial showed treatment-free survival was enhanced in patients with advanced renal cell carcinoma who received nivolumab monotherapy plus salvage nivolumab and ipilimumab maintenance.

89Zr-DFO-girentuximab improves sensitivity and specificity in identifying clear cell kidney cancer compared with any metric to date, according to an expert from the University of California, Los Angeles.

Patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who receive first-line cabozatinib after checkpoint inhibitor combination therapy appear to have early responses.

Updated results from the phase 3 CheckMate 9ER trial continue to support nivolumab plus cabozantinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

When combined with nivolumab and ipilimumab, cabozantinib appears to improve outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among the poor-risk population.

The addition of everolimus to vorolanib appears to improve outcomes in metastatic renal cell carcinoma.

Experts review key clinical data and current treatment strategies for renal cell carcinoma following updates from the 2022 IKCS meeting.

Treatment with nivolumab plus ipilimumab appears to result in overall survival and progression-free survival benefit in patients with intermediate- or poor-risk sarcomatoid renal cell carcinoma.